




EMLc

ATC codes: [P02CF01](#)

|                          |   |
|--------------------------|---|
| Indication               | Ascariasis <span>ICD11 code: <a href="#">1G33</a></span>  |
| INN                      | Ivermectin  |
| Medicine type            | Chemical agent  |
| List type                | Core (EML) (EMLc)   |
| Formulations             | Oral > Solid > tablet: 3 mg   |
| EML status history       | First added in 2017 ( <a href="#">TRS 1006</a> )<br>Changed in 2023 ( <a href="#">TRS 1049</a> )  |
| Sex                      | All   |
| Age                      | Also recommended for children   |
| Therapeutic alternatives | The recommendation is for this specific medicine  |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .  |
| Wikipedia                | <a href="#">Ivermectin</a>    |
| DrugBank                 | <a href="#">Ivermectin</a>   |

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listings for ivermectin 3 mg tablets on the EML and EMLc be amended to remove specification of scoring.

